TG 1050

Drug Profile

TG 1050

Alternative Names: TG-1050

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Transgene
  • Developer Transgene; Transgene - Tasly Pharmaceutics Group (JV)
  • Class Hepatitis B vaccines; Peptide vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 24 Oct 2017 Efficacy data from a phase I/Ib trial in Hepatitis B presented at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
  • 23 Oct 2017 Adverse events and immunogenicity data from a phase I/Ib trial in Hepatitis B released by Transgene (NCT02428400)
  • 17 Oct 2017 Transgene completes enrolment in its phase I/Ib trial for Hepatitis B in France, Canada and Germany (NCT02428400)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top